- Home
- BDRX vs ADTX Comparison
BDRX vs ADTX Comparison
Compare BDRX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDRX | ADTX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BDRX | ADTX |
|---|---|---|
| Price | $6.81 | $2.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 09-12-2025 | 11-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,945.00 |
| Revenue This Year | N/A | $15,768.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.58 | $2.20 |
| 52 Week High | $92.00 | $10,311.20 |
Technical Indicators
Market Signals| Indicator | BDRX | ADTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 44.98 |
| Support Level | $4.00 | $2.65 |
| Resistance Level | $8.94 | $3.75 |
| Average True Range (ATR) | 1.09 | 0.67 |
| MACD | 0.33 | -0.15 |
| Stochastic Oscillator | 72.28 | 15.74 |
Price Performance
Historical ComparisonAbout BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.